Viva Biotech Holdings reported no change in its authorized share capital, which remains at 4,000,000,000 ordinary shares with a par value of USD 0.000025 each, totaling USD 100,000.

The number of issued shares (excluding treasury shares) increased from 2,128,434,305 to 2,129,882,353 during October 2025. This change primarily arose from the exercise of 1,448,048 share options under a pre-IPO share incentive scheme, raising USD 178,156.24.

Following the exercise, 2,217,093 share options remained outstanding under the pre-IPO share incentive scheme. The post-IPO share option scheme continued to show 9,620,000 outstanding share options, without changes. No treasury shares were involved in any transaction during the period.